Free tool
FAERS Monitor: Vogelxo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204399 or its brand name (Vogelxo, Testosterone). Reports on generic versions are filed under their own applications.
Reports
19,084
Serious
10,933
57% of reports
Hospitalization
4,603
Death reported
780
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,467
- off label use1,232
- fatigue1,182
- nausea858
- pain778
- headache776
- diarrhoea628
- anxiety612
- asthenia598
- arthralgia595
- dizziness593
- dyspnoea549
- insomnia514
- weight decreased432
- depression428
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 169 |
| 2005 | 126 |
| 2006 | 139 |
| 2007 | 156 |
| 2008 | 188 |
| 2009 | 248 |
| 2010 | 307 |
| 2011 | 334 |
| 2012 | 875 |
| 2013 | 367 |
| 2014 | 556 |
| 2015 | 1,104 |
| 2016 | 1,061 |
| 2017 | 978 |
| 2018 | 1,138 |
| 2019 | 1,227 |
| 2020 | 1,198 |
| 2021 | 1,206 |
| 2022 | 1,419 |
| 2023 | 1,550 |
| 2024 | 1,641 |
| 2025 | 1,722 |
| 2026 | 1,375 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,075 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anxietySignal | 612 | 2.4 | 2.2 | 490 |
| insomniaSignal | 514 | 2.1 | 2.0 | 310 |
| depressionSignal | 428 | 2.1 | 1.9 | 239 |
| asthenia | 598 | 1.8 | 1.6 | 196 |
| weight decreased | 432 | 1.7 | 1.6 | 127 |
| fatigue | 1,182 | 1.7 | 1.6 | 332 |
| arthralgia | 595 | 1.6 | 1.5 | 128 |
| off label use | 1,232 | 1.6 | 1.5 | 251 |
| pain | 778 | 1.4 | 1.3 | 90 |
| headache | 776 | 1.4 | 1.3 | 77 |
| dizziness | 593 | 1.3 | 1.2 | 44 |
| drug ineffective | 1,467 | 1.2 | 1.2 | 65 |
| nausea | 858 | 1.2 | 1.1 | 28 |
| diarrhoea | 628 | 1.1 | 1.0 | 3 |
| dyspnoea | 549 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.